In conclusion, TNF-α blockers are approved to treat a variety of diseases like rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, and inflammatory bowel disease (Crohn’s disease and ulcerative colitis). This evidence concerns the gene TNF and psoriasis.